MDxHealth SA (MDXH) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

2025 earnings conference call. At this time, all participants are in the listen-only mode. Following the presentation this morning, there will be a question-and-answer session. To ask a question, you may press star and then 1 on your touch-tone phone. To withdraw your question, you may press star and 2. As a reminder, this call is being recorded. I would now like to hand over the conference to John Francis from LifeSci Advisors. Thank you and over to you. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factor section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20F. I'll now turn the call over to Michael McGarrity, Chief Executive Officer. Thanks, John. And thank you all for joining us for our third quarter 2025 Earnings Conference Call for MDX Health. With me today is Scott McMahon, Interim Chief Financial Officer. We've been very consistent in our message and mission that MDX Health is driven by three core operating principles, focus, execution, and growth. We are excited to report results that are consistent with that internal mandate, From a focus perspective, we continue to identify high-value differentiated assets as demonstrated by our recent acquisition of the exosome diagnostics business, further positioning MDX Health with the most comprehensive industry-leading menu of precision diagnostics in urology. From an initial elevated PSA to and through each point along the diagnostic pathway of prostate cancer, MDX Health ca...